CCL2 and diabetic kidney disease: The potential clinical usefulness of the TNFR1 and CCL2 tests was furthermore investigated by retrospective comparison of patients from the Sun-MACRO study who had DKD and either stable kidney function over 18 months (n = 30; baseline eGFR = 35.2) or experienced progressive loss of eGFR > 5 ml/min/yr (n = 30; baseline eGFR = 37.9) (Figure 4a and b and Supplementary Figure S14).55